Keyuan Pharmaceutical Subsidiary Adds Four Drugs to National Essential Medicines List

Regulation
โดย 财中社·Read original
Summary · why it matters

Shandong Linuo Pharmaceutical, a wholly owned subsidiary of Keyuan Pharmaceutical, has added four new varieties to the National Essential Medicines List, 2026 edition. Including existing products, the company and Linuo Pharmaceutical now have a total of 18 products included in the list. In the first quarter of 2026, Keyuan Pharmaceutical achieved revenue of 161 million yuan and net profit attributable to the parent company of 30.07 million yuan.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

山东力诺制药有限公司Private▲ Positive
Demandrelevance

As the subsidiary, Linuo Pharmaceutical added four new varieties to the list, boosting its product portfolio and demand prospects.

© 2026 MarketDXNews